Home
>
Active Pharmaceutical Ingredients
>
Other Chemical Drugs
>
Pralsetinib
for Sale
>
Pralsetinib
Pralsetinib
Unit Price:
Get Latest Price
CAS No.:
2097132-94-8
Port:
Shanghai Port
Packaging:
100g;500g;1kg
Price valid (until):
2023-08-04
Company Type:
Trader
Location:
China
Qualification:
Main Products:
Upadacitinib Hemihydrate,(S)-(+)-1-Boc-3-hydroxypyrrolidine
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferencePralsetinib is a Kinase Inhibitor. The mechanism of action of pralsetinib is as a Rearranged during Transfection (RET) Inhibitor.|Pralsetinib is an orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion product. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers.Basic Info
-
Product Name:
Pralsetinib
Other Name:Pralsetinib;BLU-667;2097132-94-8;Blu667;trans-Pralsetinib;Pralsetinib free base;UNII-1WPE73O1WV;1WPE73O1WV;cis-Pralsetinib;BLU123244
CAS No.:2097132-94-8
Molecular Formula:C27H32FN9O2
InChIKeys:GBLBJPZSROAGMF-SIYOEGHHSA-N
Molecular Weight:533.6
Exact Mass:533.26629946
UNII:1WPE73O1WV
NCI Thesaurus Code:C132295
Categories:
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Upadacitinib Hemihydrate,(S)-(+)-1-Boc-3-hydroxypyrrolidine
-
Location:
Honggutan District, Nanchang City, Jiangxi Province
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
50
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2021
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product